Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Evolus ( (EOLS) ) is now available.
On March 3, 2026, Evolus secured a new senior secured asset-based revolving credit facility of up to $30 million, with an uncommitted $10 million accordion, maturing in 2029 and secured by substantially all company assets, which adds liquidity but introduces ongoing covenant constraints and collateralized leverage. The facility, priced at adjusted term SOFR plus a margin and subject to minimum utilization and excess availability requirements, gives the company added financial flexibility to manage working capital and capital structure as it scales its injectable aesthetics portfolio.
Also on March 3, 2026, Evolus reported 2025 results showing total net revenue of $297.2 million, up 12% year over year, and fourth-quarter GAAP operating income of $4.2 million, marking a move into profitability after expense reductions and delivering a sixth consecutive year of double-digit growth. The company tightened operating costs, boosted cash to $53.8 million by year-end, and issued 2026 guidance for 10% to 13% revenue growth and modestly rising non-GAAP operating expenses, positioning it for sustainable profitability and expanding margins as new HA gel products and international launches contribute more meaningfully to growth.
The most recent analyst rating on (EOLS) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Evolus stock, see the EOLS Stock Forecast page.
Spark’s Take on EOLS Stock
According to Spark, TipRanks’ AI Analyst, EOLS is a Neutral.
The score is held back primarily by weak financial health (ongoing losses, negative equity, and leverage) and bearish technicals. This is partly offset by a strong, growth-focused earnings call with improving commercial traction and a clear profitability target timeline, while valuation is difficult to support due to negative earnings.
To see Spark’s full report on EOLS stock, click here.
More about Evolus
Evolus, Inc. is a global performance beauty company focused on building an aesthetic portfolio of consumer brands, including its flagship neurotoxin Jeuveau and a growing range of injectable hyaluronic acid gels such as Evolysse and Estyme. The company targets the injectable aesthetics market in the U.S. and internationally, leveraging a digitally enabled commercial platform and a large consumer loyalty program to drive adoption and market share gains.
Average Trading Volume: 1,036,828
Technical Sentiment Signal: Sell
Current Market Cap: $278.1M
Learn more about EOLS stock on TipRanks’ Stock Analysis page.